Literature DB >> 27432918

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Rafael Rosell1, Niki Karachaliou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27432918     DOI： 10.1200/JCO.2016.68.3458

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors:  Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Liquid Biopsy in Non-Small Cell Lung Cancer.

Authors:  Miguel A Molina-Vila; Clara Mayo-de-Las-Casas; Ana Giménez-Capitán; Núria Jordana-Ariza; Mónica Garzón; Ariadna Balada; Sergi Villatoro; Cristina Teixidó; Beatriz García-Peláez; Cristina Aguado; María José Catalán; Raquel Campos; Ana Pérez-Rosado; Jordi Bertran-Alamillo; Alejandro Martínez-Bueno; María-de-Los-Llanos Gil; María González-Cao; Xavier González; Daniela Morales-Espinosa; Santiago Viteri; Niki Karachaliou; Rafael Rosell
Journal:  Front Med (Lausanne)       Date:  2016-12-23

Review 3.  Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.

Authors:  Valentina Mazza; Federico Cappuzzo
Journal:  Appl Clin Genet       Date:  2017-07-26

4.  Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Authors:  Carles Codony-Servat; Jordi Codony-Servat; Niki Karachaliou; Miguel Angel Molina; Imane Chaib; Jose Luis Ramirez; Maria de Los Llanos Gil; Flavio Solca; Trever G Bivona; Rafael Rosell
Journal:  Oncotarget       Date:  2017-07-18

5.  Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.

Authors:  Jessica Garcia; Arnaud Gauthier; Gaëlle Lescuyer; David Barthelemy; Florence Geiguer; Julie Balandier; Daniel L Edelstein; Frederick S Jones; Frank Holtrup; Mickael Duruisseau; Emmanuel Grolleau; Claire Rodriguez-Lafrasse; Patrick Merle; Sébastien Couraud; Léa Payen
Journal:  Mol Diagn Ther       Date:  2021-03-03       Impact factor: 4.074

6.  Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs.

Authors:  Hsiang-Ling Ho; Fang-Yu Wang; Chi-Lu Chiang; Chun-Ming Tsai; Chao-Hua Chiu; Teh-Ying Chou
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

7.  Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.

Authors:  Kang-Yi Su; Jeng-Sen Tseng; Keng-Mao Liao; Tsung-Ying Yang; Kun-Chieh Chen; Kuo-Hsuan Hsu; Pan-Chyr Yang; Sung-Liang Yu; Gee-Chen Chang
Journal:  PLoS One       Date:  2018-11-16       Impact factor: 3.240

Review 8.  EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Cancer Res       Date:  2019-01       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.